MedTrace Logo

Research on the Use of Probiotics in the Prevention and Treatment of Inflammatory Bowel Disease

NCT06781827 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-04-04

No results posted yet for this study

Summary

This project involves the use of oral Lactobacillus reuteri as an adjunct therapy for 8 weeks. Endoscopic observation of intestinal inflammation will be conducted at 1 month, 3 months, 6 months, and 12 months after the administration of the drug. Intestinal fluid will be collected endoscopically for 16S RNA analysis to assess changes in the gut microbiota. Inflammatory changes in the patients will be detected through peripheral blood tests, and fecal calprotectin levels will be measured to evaluate the progression of the disease.

Conditions

Interventions

DIETARY_SUPPLEMENT

Probiotic

The experimental phase of the study lasts 8 weeks and each patient will be visited 4 times (January, March, June, and December).

DIETARY_SUPPLEMENT

Maltodextrin

The experimental phase of this study had last 8 weeks and each patient will make 4 visits (January, March, June, and December).

Sponsors & Collaborators

  • Wecare Probiotics Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2025-10-30
Completion
2025-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06781827 on ClinicalTrials.gov